August 20, 2015 / 1:05 PM / 2 years ago

BUZZ-Palatin Technologies Inc: Rival drug maker Sprout being bought by Valeant

** Specialty drug maker’s shares up 16 pct at $1.13 premarket after Canada’s Valeant Pharmaceuticals International Inc says it will buy Sprout Pharmaceuticals

** Palatin is creating drug, called bremelanotide, that could rival Sprout’s drug, Addyi, which became first approved treatment this week for low sexual desire in premenopausal women

** Approval for Sprout’s drug seen by industry experts as more likely to help build market for better future rival drugs

** Valeant’s U.S-listed shares up 0.4 pct at $245.92 premarket

** Up to Wednesday’s close, stock had risen 33 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below